At its Pharmacy and Technology Conference, the National Association of Chain Drug Stores presented Doug Long with the prestigious Harold W. Pratt Award.
At its Pharmacy and Technology Conference, the National Association of Chain Drug Stores (NACDS) presented Doug Long with the prestigious Harold W. Pratt Award.
The annual award, named for Pratt, who worked at Walgreens for 43 years and became the industry’s first director of professional services, recognizes individuals whose activities have contributed to the promotion, recognition, and improvement of the practice of pharmacy within the chain drug industry, according to an NACDS statement.
For the last 23 years of Long’s 40 years in pharmacy, he has worked at IMS Health, implementing health databases, creating relationships with manufacturers and associations, and developing new products. Long currently serves as vice president of industry relations for the company.
“Doug Long has earned a reputation as one of the foremost ‘go-to’ sources when it comes to the numbers and trends behind this industry,” said NACDS President and CEO Steven C. Anderson, IOM, CAE. “Doug has built a reputation of synthesizing the latest industry information and forecasting ‘what’s next’ in ways that help stakeholders understand what it means for their day-to-day businesses. NACDS is honored to bestow the distinguished Harold W. Pratt award upon Doug Long and we thank him for his continued service to pharmacy.”
Long is known for his annual Industry Year in Review, which features trends and forecasts in the U.S. market, and he is a speaker for several industry groups. Prior to his work with IMS Health, he served in various sales and marketing roles for Nielsen Market Research.
You May Also Be Interested In…
Long recently spoke with Drug Topics about generic pharmaceutical trends and the potential influence of the Affordable Care Act on various stakeholders within the industry. Here are the links to the articles:
Floodgates open - Pharmacists, generic drug makers to benefit over next two years
ACA means ups, downs for various stakeholders in the generics game